Cost Effectiveness of Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| May 2008 | September 2008 | Reimbursement recommended. |
A summary of the main findings are included in the attached document.